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Abstract
Background: The precise nature of how cell type specific chromatin structures at enhancer sites affect gene
expression is largely unknown. Here we identified cell type specific enhancers coupled with gene expression in two
different types of breast epithelial cells, HMEC (normal breast epithelial cells) and MDAMB231 (triple negative breast
cancer cell line).
Results: Enhancers were defined by modified neighboring histones [using chromatin immunoprecipitation
followed by sequencing (ChIP-seq)] and nucleosome depletion [using formaldehyde-assisted isolation of regulatory
elements followed by sequencing (FAIRE-seq)]. Histone modifications at enhancers were related to the expression
levels of nearby genes up to 750 kb away. These expression levels were correlated with enhancer status (poised or
active), defined by surrounding histone marks. Furthermore, about fifty percent of poised and active enhancers
contained nucleosome-depleted regions. We also identified response element motifs enriched at these enhancer
sites that revealed key transcription factors (e.g. TP63) likely involved in regulating breast epithelial enhancer-mediated
gene expression. By utilizing expression data, potential target genes of more than 600 active enhancers were identified.
These genes were involved in proteolysis, epidermis development, cell adhesion, mitosis, cell cycle, and DNA replication.
Conclusions: These findings facilitate the understanding of epigenetic regulation specifically, such as the relationships
between regulatory elements and gene expression and generally, how breast epithelial cellular phenotypes are
determined by cell type specific enhancers.
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Background
The human genome has 22 chromosome pairs and 2 sex
chromosomes. This single genome gives rise to several
hundred distinct cell types including epithelial, neuronal,
lymphocytic, germ, etc. In 2003, the human genome was
completely sequenced, and it ushered in a new under-
standing of the breadth and diversity of primary coding
sequences [1]. However, the specific mechanism(s),
explaining how one genome gives rise to a large num-
ber of diverse cells and tissues, remains unclear. What
has become apparent is that dynamic gene expression
levels determined by regulatory networks, whose building
blocks are in turn governed by epigenetic chromatin states,
may explain how cellular phenotypes are defined.
Genomic DNA is organized into chromatin; 147 base
pairs of DNA are wrapped around two copies of each of
the core histone proteins, namely H2A, H2B, H3, and H4,
forming a single octameric nucleosome core particle.
Chromatin is found in two forms: hetero- and euchromatin.
Heterochromatin is highly condensed, forming tightly pack-
aged chromatin. In this compact state, a high density of
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repetitive DNA elements such as satellite DNA and trans-
posable elements are found, and the dense packing of DNA
makes it less likely for transcription factors to bind [2]. In
euchromatin, by contrast, chromatin is relatively ‘open’ or
loosely packaged, forming ‘beads on a string’ structures. In
this open form, gene regulatory proteins may easily bind to
the DNA, and nuclear processes such as transcription can
be performed and influenced by dynamic nucleosome posi-
tioning [3]. Nucleosome position and histone marks play
important roles to demarcate regulatory elements such as
promoters, enhancers, and repressed regions.
Enhancers are non-directional regulatory elements
that control gene expression at a distance on linear
DNA [4]; i.e. they reside in so-called non-coding DNA
regions such as intergenic regions and introns. Several his-
tone marks (H3K4me1, H3K4me2, H3K9Ac, H3K14Ac,
H3K27Ac) [5,6] and nucleosome-depleted regions have
been shown to correlate or to be associated with regions
that display enhancer activity; nucleosome-depleted
regions can be visualized by DNaseI-sensitivity and/or
Formaldehyde-Assisted Isolation of Regulatory Elements
(FAIRE) [7]. Enhancers generally contain DNA-recognition
motifs for transcription factors, which regulate gene expres-
sion upon binding, and loop to the transcriptional start sites
of target genes [4].
Recently, a number of studies investigated the roles of
regulatory elements, distal from transcription start sites
(TSS) (i.e. enhancers), and revealed that the multiplicity
of cell states was determined by tissue-specific distal
regulatory elements [7,8]. In the present study, we
hypothesized that cell type specific enhancers may dis-
tinguish breast epithelial cells with different phenotypes.
In order to identify such specific enhancers related to
the maintenance of distinct breast epithelial phenotypes,
human mammary epithelial cell (HMEC) and breast cancer
cell line (MDAMB231) were chosen to study, representing
extremes of breast epithelial cells. In addition, both cell
types were selected because they have been shown to be
estrogen receptor (ER) negative: MDAMB231 is a triple-
negative breast cancer cell line [9-12]. It is known that
breast cancer (BCa) can arise from the transformation of a
normal ER-negative mammary epithelial cell [13]. Previous
studies support the notion that epithelial to messenchymal
transition (EMT) in breast cancer is linked to the triple
negative (ER-, PR-, HER2-) breast cancer subgroup and
even to cancer stem cells [14-16]. However, it has been
shown that ER signaling can regulate EMT [17]. The pres-
ence of ER in certain BCa cells may complicate analyses by
having differently regulated genes and changes in chroma-
tin structures upon ER binding to regulatory elements
[18,19]. By using ChIP-seq and FAIRE-seq methods, we
identified enhancers, which were unique to each cell type
of breast epithelial cells (i.e. HMEC and MDAMB231) –
we specifically excluded ER + cell lines from our analyses
for reasons alluded to above. The expression profiles of
genes in these two types of cells along with histone
marks were investigated in order to identify the target
genes of cell type specific enhancers. In our view, in-
formation gained using the approaches described in
this study will aid the understanding of epigenetic
regulation and breast cancer biology.
Results and discussion
Characterization of breast epithelial cell type specific
enhancers
Identification of enhancer specific histone modification
mark, H3K4me1 by ChIP-seq, revealed 110,715 peaks
in both cell types. Unlike other histone marks such as
H3K4me3 and H3K27Ac, the overlap of H3K4me1
peaks between two cell types were only 22 percent for
HMEC and 70 percent for MDAMB231 (Additional file
1: Figure S1 and Additional file 2: Table S1, Table S2,
Table S3). This indicated that large numbers of enhancers
defined by this histone modification mark were unique to
either cell type, and there were relatively more H3K4me1
marked enhancers in HMEC than MDAMB231. For fur-
ther downstream analysis, we selected the top 2,000 most
robust cell type specific H3K4me1 sites (Additional file 2:
Table S4, Table S5) ranked by fold-change of ChIP-seq tags
between two cell types using findPeaks software from
HOMER (http://homer.salk.edu/homer/) (see Methods)
[20]. In order to verify the method used to identify cell type
specific enhancers, we compared our HMEC specific en-
hancer loci (HSEL) with enhancers classified by using a
multivariate Hidden Markov Model in HMEC from EN-
CODE database [21]. Ninety-seven percent of HSEL (n =
1940) overlapped with HMM enhancers (42 percent with
weak enhancers in HMM, 58 percent with strong en-
hancers in HMM), indicating that our method is applicable.
At HMEC specific enhancer loci (HSEL), H3K4me1 marks
were highly enriched in HMEC, compared to MDAMB231
with more than 60 fold higher mean density of H3K4me1
ChIP-seq tags (Figure 1A). To illustrate, we selected a
distinct HSEL located in the intron of CDH3 and 60 kb
upstream of the CDH1’s transcription start site. CDH1 and
CDH3 encode calcium-dependent cell-cell adhesion
glycoproteins, E-cadherin and P-cadherin, respectively.
E-cadherin is expressed in most normal epithelial cells,
and loss of E-cadherin expression has been observed in
various tumors including breast cancer [22-24]. Unlike
E-cadherin, P-cadherin is expressed in limited epithe-
lial tissues, and it has been reported that this gene is
aberrantly expressed in breast cancer cells [25-28].
Similarly, we identified MDAMB231 specific enhancer loci
(MSEL) unique in the MDAMB231 cell type (Figure 1B).
An example of such a MSEL site is located 20 kb upstream
from the transcription start site of BMP4, which encodes a
bone morphogenetic protein 4 (BMP4). BMPs are first
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detected in extracts of bone and they regulate various de-
velopmental processes [29]. BMP4 is involved in develop-
ment of mammary gland and required for migration and
invasion of breast cancer [29-31].
Next, we investigated the genomic distributions of the
HSEL and MSEL. Most of the HSEL and MSEL specific
marks were found in introns and intergenic regions
(Additional file 1: Figure S2A, S3A). The HSEL and MSEL
were distributed evenly throughout the genome, with no
specific chromosomal enrichment (Additional file 1: Figure
S2B and Figure S3B). Remarkably, although the two sets of
putative enhancer groups were mutually exclusive (by selec-
tion), some of them still appear to cluster in the same gen-
omic regions as exemplified by chromosome 9 (Figure 1C).
These data seem to be consistent with the finding that cell
type specific enhancers with related functions cluster in
chromosomal regions with correlated gene expressions in
different cell types [32]. These speculative enhancer clusters
may be related to the high density of TSSs, high density of
pioneer protein binding, and/or chromatin structures at
these regions. In order to test these possibilities, further in-
vestigations near the enhancer clusters such as calculating
gene density, transcription factor binding, analyzing DNA
methylation, and nuclear lamina associated domains are
required.
Nearby gene expression change by cell type specific
enhancers
The next biological question was to determine which genes
might be targets of the cell type specific enhancer loci iden-
tified above (HSEL and MSEL). To this end, the differen-
tially expressed genes in HMEC and MDAMB231 were
analyzed using published data [33] and then matched to
the cell-type specific enhancers identified here. Several ap-
proaches were used to examine the relationships between
cell type specific enhancers and gene expression.
In the first approach, we selected the highest confi-
dence cell type specific genes and examined their distri-
bution relative to cell type specific enhancers. For this
purpose, genes with a p-value < 0.05 (3,174 genes for
HMEC, 2,670 genes for MDAMB231) were ranked based
on their fold-change in two cell type. The top 300 differ-
entially expressed genes, which represent about the top
10 percent of the genes, were selected and statistical
enrichment analyses were performed, using a fixed-
distance metric of 100 kb to the nearest enhancer site.
There were twice as many overexpressed genes in HMEC
than randomly sampled genes (see Methods), whose tran-
scription start sites were located within 100 kb of HSEL
(109 genes out of top 300, which showed higher expression
in HMEC than MDAMB231 vs. 54 out of 300 random con-
trol genes). Similarly, there were 1.9 times as many overex-
pressed genes in MDAMB231 than randomly sampled
genes, whose transcription start sites were located within
100 kb of MSEL (104 out of top 300 overexpressed genes
in MDAMB231 vs. 55 out of 300 random control genes)
(Figure 2A). Under the hypothesis of independent assign-
ment of the feature, cell type specific enhancers and overex-
pression, we found that the number of differentially
expressed genes having HSEL would be between 45 and 70
genes (95% confidence interval) by direct simulation (k =
100,000). Similarly, the number of differentially expressed
genes having MSEL would be between 42 and 67 (95% con-
fidence interval) if the relationship between expression and
cell type specific enhancer was independent. The above
reported numbers of 109 and 104 for overexpressed genes
(in HMEC and MDAMB231, respectively) with cell type
specific enhancers (HSEL and MSEL, respectively) fell out-
side of these intervals. Conversely, the reported numbers of
37 and 29 for underexpressed genes (i.e. overexpressed
genes in the other cell type) in HMEC and MDAMB231,
respectively with cell type specific enhancers (HSEL and
MSEL, respectively) were below 45 and 42 (95% confi-
dence). Therefore, these data suggest that overexpressed
genes in one cell type (HMEC or MDAMB231) are
enriched in the vicinity of cell type specific enhancers HSEL
and MSEL respectively, and this enrichment is accompan-
ied by a concomitant depletion of cell type specific en-
hancers from the other cell type.
In a second approach, we centered our analysis on the
cell type specific enhancers and compared the expres-
sion profile of genes within a 100 kb window on either
side of the HSEL or MSEL. If it is indeed the case that
there is a relationship between the presence of cell type spe-
cific enhancers and differentially expressed genes, then we
should be able to detect an effect of such enhancers on
nearby gene expression. On average, the expression levels
of genes with HSEL (1,418 genes, 2,184 probes) were sig-
nificantly higher in HMEC than MDAMB231 as indicated
by the plotted ratio, compared to control genes, which
were not near HSEL (Additional file 1: Figure S4A and
Figure 2B). Likewise, the average expression levels of
(See figure on previous page.)
Figure 1 Cell type specific enhancer loci identification in breast epithelial cells (HMEC and MDAMB231). (A) H3K4me1 ChIP-seq tags from both
cells at the center of HMEC specific enhancer loci (HSEL) were graphed in the heatmap (red: higher density) (left). Mean density of H3K4me1 ChIP-seq tags
from both cells at the HSEL (top right). An example of the HSEL was located in the intron of CDH3 gene, near CDH1 gene (red arrow) (bottom right). (B)
H3K4me1 ChIP-seq tags from both cells at the center of MDAMB231 specific enhancer loci (MSEL) were graphed in the heatmap (red: higher density) (left).
Mean density of H3K4me1 ChIP-seq tags from both cells at the MSEL (top right). An example of the MSEL located 20 kb upstream of the BMP4 gene (red
arrow) (bottom right). (C) Genomic distribution of cell type specific enhancer loci in chromosome 9 (red: HSEL, green: MSEL, black: transcription start sites).
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genes with MSEL (1,405 genes, 2,165 probes) were
higher in MDAMB231 than HMEC as indicated by the
plotted ratio, compared to control genes, which were
not near MSEL (Additional file 1: Figure S4B and
Figure 2B). In addition, we plotted all the genes within
a 100 kb window on either side of the HSEL or MSEL
in a scatter plot with x-axis for expression levels in
HMEC and y-axis for expression levels in MDAMB231.
Among genes within a 100 kb window on either side of
the HSEL, there were more overexpressed genes in
HMEC than in MDAMB231. Conversely, among genes
within a 100 kb window on either side of the MSEL,
there were more overexpressed genes in MDAMB231
than in HMEC (Additional file 1: Figure S5). Collectively,
these results indicated that cell type specific enhancers
were well correlated with differentially expressed genes in
both cell types.
In order to infer the physical range over which the
presence of cell type specific enhancers influences gene
expression levels, we examined the fraction of differen-
tially expressed genes as a function of distance from the
enhancer. To this end, genes were grouped in increasing
window sizes around the cell type specific enhancers
from 20 kb up to 2 Mb. All the genes within given win-
dow sizes of cell type specific enhancers were then cate-
gorized as either overexpressed in HMEC, overexpressed
in MDAMB231, or not differently expressed genes.
Genes nearby HMEC specific enhancers were expressed
higher in HMEC compared to MDAMB231, but the effect
decreased as the distance between HSEL and nearby genes
increased in general. For instance, the overexpressed genes
in HMEC were 1.7 times more than overexpressed genes in
MDAMB231 within a 100 kb window on either side of
these HSEL (p = 4.2e-32) (Figure 2C, Additional file 1:
Figure S6A and Additional file 2: Table S6). However, the
overexpressed genes in HMEC were only 1.2 times more
than overexpressed genes in MDAMB231 within a 750 kb
window on either side of these HSEL. There were still rela-
tively more overexpressed genes in HMEC even within a
2 Mb window on either side of the HSEL. This maybe due
to the fact that average expression value for all genes
probed in the microarray was a little bit higher in HMEC
as a possible result of having more enhancers in HMEC,
compared to MDAMB231 (Additional file 1: Figure S7).
Among control genes, which were not near HSEL, the
overexpressed genes in HMEC were about 1.2 times more
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Figure 2 Expression level of nearby genes of the HSEL and MSEL. (A) Number of genes with cell type specific enhancer loci (i.e. HSEL,
MSEL) from top 300 overexpressed genes in MDAMB231 (blue), top 300 overexpressed genes in HMEC (red), and three randomly selected
300 gene datasets as controls (orange). The enrichment of genes with cell type specific enhancer loci in each group was calculated by
performing chi-square test between groups. (B) Log fold change of nearby gene expression boxplot for the HSEL and MSEL (in windows of
100 kb). Student t-test was applied between groups in order to calculate p-values. Nearby genes of cell type specific enhancer loci (HSEL
(C), MSEL (D)) were categorized to three groups; overexpressed genes in MDAMB231 (blue), overexpressed genes in HMEC (red), and no
change in gene expression (green), and fraction of genes for each category was graphed. Eight different window sizes were used for the
nearby gene distance from cell type specific enhancer loci: from 20 kb windows of cell type specific enhancer loci (±20 kb of HSEL/MSEL)
up to 2 Mb windows (±2 Mb of HSEL/MSEL).
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than overexpressed genes in MDAMB231 regardless of
the distance (Additional file 1: Figure S8A). Therefore, we
can interpret these results that there were significantly
more overexpressed genes in HMEC when the distance
from HSEL was smaller than 750 kb. The effect decreased
if the window size increased from 750 kb to 2 Mb. When
the distance between HSEL and nearby genes was bigger
than 750 kb, the fraction of overexpressed genes in HMEC
was not statistically significant, compared to control genes
(p > 0.17) (Additional file 2: Table S6).
Conversely, more genes nearby MDAMB231 specific
enhancers were expressed higher in MDAMB231, com-
pared to HMEC when the window size was smaller than
750 kb. The overexpressed genes in MDAMB231 were
1.4 times more than overexpressed genes in HMEC
within a 100 kb window on either side of these MSEL
(p = 6.76e-17) (Figure 2D, Additional file 1: Figure S6B).
The effect of MSEL on increasing gene expression in
MDAMB231 vs. HMEC was most significant when the
window size between MSEL and nearby gene was 100 kb
(Additional file 2: Table S6). However, the effect de-
creased as the window size increased. Thus, almost the
same number of overexpressed genes in MDAMB231
(n = 1,687) and overexpressed genes in HMEC (n =
1,679) was found within a 750 kb window on either
side of these MSEL (p = 0.86) (Figure 2D, Additional
file 1: Figure S6B). In control genes, which were not
near MSEL (from window size 20 kb to 2 Mb), there
were more overexpressed genes in HMEC than overex-
pressed genes in MDAMB231 regardless of the dis-
tance (Additional file 1: Figure S8B and Additional file
2: Table S6).
As another control dataset, we selected 2,000 H3K4me1
sites found in both cell types (called shared enhancers)
(Additional file 1: Figure S9 and Additional file 2: Table S7),
and investigated gene expression levels near the shared en-
hancers from window size 20 kb to 2 Mb. Unlike genes
near cell type specific enhancers, there were approximately
the same number of overexpressed genes in HMEC and
overexpressed genes in MDAMB231 across the window
size from 20 kb to 2 Mb (Additional file 1: Figure S10,
Additional file 2: Table S6). For example, there were
630 overexpressed genes in MDAMB231 and 673 over-
expressed genes in HMEC within a 100 kb window
of shared enhancers (p > 0.11). Within a 2 Mb window
of shared enhancers, 2,206 overexpressed genes in
MDAMB231 and 2,258 overexpressed genes in HMEC
were found.
As Chepelev et al [34] and Sheffield et al [35] sug-
gested, our findings further supported that on average,
cell type specific enhancers seemed to regulate genes
closer than 100 kb, but the effect decreased as the gene
distance increased: The significance of correlation was
evident with nearby genes as far 750 kb from cell type
specific enhancers (Figure 2B,C,D, Additional file 1: Figure
S11). These findings remained consistent when we investi-
gated genes at each distance interval from window size
20 kb to 2 Mb of enhancers (Additional file 1: Figure S12,
Additional file 2: Table S8). Overall, cell type specific en-
hancers were correlated with nearby genes, which were
differentially expressed in both cell types.
Enhancer status and nearby gene expression level change
Recently, several groups categorized enhancers into a
number of functional classes by using histone modifi-
cations [36,37]. From these studies, it became apparent that
H3K27Ac marks demarcate active enhancers, whereas
H3K4me1 marks define both active and poised enhancers.
In other words, enrichment of H3K4me1 and H3K27Ac
correlated with active and engaged enhancers [38,39],
whereas poised enhancers (H3K4me1 without H3K27Ac
marks) correlated with relatively lower expression levels of
the target genes [36].
In order to determine whether the expression levels of
nearby genes in our study were also correlated with the
enhancer status as defined above, we classified HSEL as
poised (n = 1,270) or active (n = 730) using K means
linear clustering with H3K27Ac ChIP-seq data [40]
(Figure 3A, Additional file 2: Table S4). When classify-
ing the MSEL in a similar manner, 1,021 poised MSEL
and 979 active MSEL were identified (Figure 3B, Additional
file 2: Table S5).
Next, the expression levels of nearby genes (+/-100 kb)
of the poised and active enhancer groups as defined above
were assessed by randomly selecting 500 poised HSEL, 500
active HSEL, 500 poised MSEL, and 500 active MSEL. On
average, genes near poised HSEL were significantly overex-
pressed in HMEC relative to MDAMB231 (Figure 3C, blue
boxplot): genes located outside of HSEL were not differen-
tially expressed (Figure 3C, red boxplot). The average ex-
pression levels of genes located near active HSEL were
even higher in HMEC than MDAMB231 (Figure 3C, green
boxplot). Conversely, on average, genes near poised MSEL
were expressed at higher levels in MDAMB231 than in
HMEC, and the expression levels in MDAMB231 were
even higher for genes near active MSEL (Figure 3C, com-
pare purple and crimson vs. yellow boxplots). Therefore,
cell type specific enhancer status defined by histone modi-
fications was positively correlated with cell type specific
regulation of nearby gene expression.
Detection of Nucleosome-depleted regions at both poised
and active enhancers
In order to investigate open chromatin regions at cell-
type specific enhancers, we first intersected FAIRE-seq
peaks (n = 57,489) from HMEC with the HMEC specific
enhancer loci (HSEL). Most of these open chromatin re-
gions in enhancers correspond to nucleosome-depleted
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regions [7,41,42]. Among our 2,000 HSEL, HMEC FAIRE
peaks were found with surrounding enhancer histone
marks in 1,004 HSEL (Additional file 1: Figure S13A, B).
Among these sites, 550 HSEL were poised, and 454 of them
were putatively active (Figure 4A). On the other hand,
among our 2,000 MSEL, 1,047 coincided with MDAMB231
FAIRE peaks (n = 46,552) with surrounding enhancer his-
tone marks (Figure 4B, Additional file 1: Figure S13C, D).
Among them, 512 were poised, and 535 were putatively
active (Figure 4B). As a priori defined, H3K4me1 marks
were more enriched than H3K27Ac in poised enhancers,
and H3K27Ac density was much higher than H3K4me1 in
active enhancers. However, the mean density of FAIRE
peaks in either poised or active enhancers was similar
(Figure 4A,B). Overall, regardless of enhancer status, about
fifty percent of enhancers were at nucleosome-depleted re-
gions. Although one study reported that H3K27Ac is not
enriched in enhancers without DNaseI hypersensitive sites
[43], our results suggested that the H3K27Ac mark was not
dependent on the presence of nucleosome-depleted re-
gions, as detected by FAIRE. Poised enhancers still retained
nucleosome depletion even without H3K27Ac enrichment
(Figure 4C).
We investigated this relationship even further by correl-
ating FAIRE signals with the expression levels of genes
within a 100 kb window of the signal. When the top 2,000
cell-type specific nucleosome-depleted regions were se-
lected and nearby gene expression levels were calculated,
significant correlations were apparent between the nearby
gene expression levels and presence of cell type specific
FAIRE signals (data not shown).
In order to determine whether the presence of FAIRE
peaks in HSEL and MSEL can further increase the apparent
specificity of association with cell-type specific gene expres-
sion, we again examined gene expression. When the poised
and active cell type specific enhancers were further classi-
fied according to FAIRE signals, and the expression level
differences of nearby genes (+/-100 kb) were assessed,
HSEL with FAIRE signals seemed to more strongly associ-
ate with nearby cell type specific gene expression levels at
both enhancer states (Additional file 1: Figure S14A, C).
However, there was no statistically significant difference in
gene expression levels near MSEL by the presence of FAIRE
signals (Additional file 1: Figure S14B, C). In our analyses,
FAIRE signals in enhancers seemed to significantly affect
gene expression levels in normal breast epithelial cells, but
not in the breast cancer cells. In addition, when all of the
FAIRE signals in HMEC (n = 57,489) were intersected with
11 different histone modification marks (i.e. H3K27me3,
H2A.Z, H3K9me3, H3K79me2, H3K36me3, H3K20me1,
H3K9Ac, H3K4me2, H3K4me3, H3K27Ac, H3K4me1),
more than ninety-seven percent of peaks coincided
with above histone marks (n = 55,986). Therefore, the
regions identified by FAIRE seem to represent a sub-
group of regions enriched by various histone marks
[44,45], indicating the importance of histone marks
surrounding the FAIRE signals than FAIRE signals
themselves.
Transcription factors in breast epithelial cell type specific
enhancers
Nucleosome-depleted regions are known as sites of tran-
scription factor occupation [18,46]. Therefore, we searched
for such motifs, which may be found at FAIRE peaks in
HSEL and MSEL by using TRANSFAC and JASPAR
[47,48]. This database also contains motif matrices from
best-scoring TF binding sites identified with a ChIP-chip or
ChIP-seq fragment. The search was restricted to the re-
sponse elements of factors that were known to be expressed
in these cells [33]. A chi-square test was performed be-
tween the groups to measure the enrichment of transcrip-
tion factor response elements (summarized in a flow
diagram, see Additional file 1: Figure S15).
The results of transcription factor motif searches at
FAIRE signals in the HSEL and MSEL revealed that sev-
eral response elements such as TP63, TFCP2, SMAD3,
NF1, and EP300 elements were more highly enriched at
HSEL than at MSEL (Table 1). On the other hand, FOS,
FOXA, and TCF4 were highly enriched in the FAIRE re-
gions at the MSEL, compared to at HSEL. TP63, which
is the most significantly enriched motif in HSEL com-
pared to MSEL, is known to act as a sequence-specific
DNA binding transcriptional activator or repressor.
TP63 plays an essential role in epidermal development
and regulates multiple pathways such as BMP and Notch
signaling [49,50]. TP63 has complicated roles in human
cancer: some studies reported its tumor suppressor ac-
tivity in breast and bladder cancers, but it acted as an
oncogene in lung cancer cells [51-53]. It may be re-
quired in conjunction with TP73/p73 for initiation of
p53/TP53 dependent apoptosis in response to genotoxic
insult and the presence of activated oncogenes [54,55].
In order to test whether transcription factors, which
were identified by motif searches, physically bind to
(See figure on previous page.)
Figure 3 Poised and active enhancers. (A) H3K4me1 and H3K27Ac ChIP-seq tags from HMEC at the HSEL were graphed in the heatmap (red: higher
density) (left). Mean density of H3K4me1 and H3K27Ac ChIP-seq tags from HMEC at the poised HSEL (top right) and the active HSEL (bottom right) (B)
H3K4me1 and H3K27Ac ChIP-seq tags from MDAMB231 at the MSEL were graphed in the heatmap (red: higher density) (left). Mean density of H3K4me1
and H3K27Ac ChIP-seq tags from MDAMB231 at the poised MSEL (top right) and the active MSEL (bottom right) (C) Log fold change of nearby gene
expression boxplot for the poised/active HSEL and poised/active MSEL. Student t-test was applied between groups in order to calculate p-values.
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breast epithelial cell type specific enhancers, we per-
formed site-specific ChIP analyses by using TP63 anti-
body in both HMEC and MDAMB231 cells. As the
motif search suggested, TP63 was enriched in multiple
cell type-specific enhancers of HMEC, located in the in-
tron of the TP73 gene in 1p36.32, gene desert region in
2q13, intron of SCHIP1 gene in 3q25.33, and gene desert
region in 10q24.33. However, at the same enhancer no
TP63 binding was detected in MDAMB231 cells; neither
enhancer histone marks nor a FAIRE signal was detected in
MDAMB231 cells (Additional file 1: Figure S16, Figure
S17). The observation that TP63 binding coincided with
open chromatin regions marked by enhancer histone modi-
fications, may be related to their relative expression and
protein levels and/or to the fact that the respective cell-
type specific enhancers were more or less permissive
to transcription factor binding due to their chromatin
structures. In order to further investigate this, we mea-
sured the expression level of TP63 gene in HMEC and
MDAMB231 by performing additional RT-qPCR and
Figure 4 Poised and active enhancers with FAIRE signals. (A) Mean density of H3K4me1, H3K27Ac ChIP-seq, and FAIRE-seq tags from HMEC
at the center of poised (left) or active (right) HSEL, which were intersected with HMEC FAIRE (B) Mean density of H3K4me1, H3K27Ac ChIP-seq,
and FAIRE-seq tags from MDAMB231 at the center of poised (left) or active (right) MSEL, which were intersected with MDAMB231 FAIRE (C) UCSC
genome browser screenshots for examples of poised cell type specific enhancer loci with FAIRE signal (left: poised HSEL, right: poised MSEL)
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re-visiting the data from microarray data (Additional
file 1: Figure S18). Although there was a small discrepancy
between expression levels among exons we measured,TP63
gene was expressed at higher levels in HMEC than
MDAMB231. We also measured protein levels of TP63
using western blots, and found that TP63 protein level was
higher in HMEC than MDAMB231 (Additional file 1:
Figure S19). Therefore, our data here cannot distinguish if
cell type specific TP63 binding in these enhancers is due to
its protein level and/or chromatin accessibility. However,
recent studies reported that TP63 binding may require ac-
cessible chromatin and/or additional transcription factors
that cooperatively associate with DNA [56,57]. Further in-
vestigations on TP63 activity such as its possible ability to
penetrate local nucleosome structures as a pioneer protein
or recruit other factors will facilitate the understanding of
TP63 binding mechanism in breast cancer.
When we further compared the enriched motifs be-
tween the poised and active enhancers, besides above
factors, NR3C1, NFATC2, FOXQ1, and PBX1 motifs
were significantly enriched at active HSEL than poised
HSEL. Conversely, VDR, TFAP2A, TFCP2, BHLHE41,
and NFIC motifs were more enriched at poised HSEL
than active HSEL (Additional file 2: Table S9). Amongst
the MSEL, FLI1//EWSR1, GABPA, ELK1, MYB, and
NR2F1 were enriched at active MSEL than poised MSE.
Conversely, FOXA motifs were significantly enriched in
poised MSEL relative to active MSEL (Additional file 2:
Table S10).
Identification of target genes for each cell type specific
enhancer
Nearby genes of cell type specific enhancers (i.e. HSEL
and MSEL) were studied to identify more specifically
those target genes, whose expression levels were regu-
lated mainly by cell type specific enhancers. For each cell
type, there were about 1,400 genes (1,418 for HSEL,
1,405 for MSEL) in 100 kb windows around cell type
specific enhancers. Among them, 376 genes were found in
both windows of cell-type specific enhancers since some
cell-type specific enhancers were clustered. In order to
identify specific target genes for each cell type specific en-
hancer, the overlapped genes were excluded for further
analysis. Among the genes located near HSEL only (n =
1,042), 59 percent (n = 617) had higher expression levels
Table 1 Motif enrichment in cell type specific enhancers
Motif
name
Number of
motif in HSEL
Number of motif
in MSEL
P-value Database
TP63 116 4 7.36E-30 TRANSFAC
FOS 398 650 2.90E-24 JASPAR
FOS 352 589 3.09E-21 JASPAR
FOS 49 173 6.27E-19 TRANSFAC
FOS 42 183 2.56E-17 TRANSFAC
FOXA1 277 468 8.01E-16 JASPAR
FOS 352 585 5.15E-14 JASPAR
FOS 39 133 9.59E-14 TRANSFAC
FOXA2 339 514 1.92E-12 JASPAR
FOS 32 143 2.92E-12 TRANSFAC
FOXA1 47 124 4.37E-12 TRANSFAC
FOXA1 32 134 6.36E-12 TRANSFAC
FOS 306 524 6.91E-12 JASPAR
TCF4 95 215 2.33E-10 TRANSFAC
FOXA1 49 117 3.29E-10 TRANSFAC
FOXA1 34 127 4.05E-10 TRANSFAC
FOXA2 9 59 1.41E-08 TRANSFAC
FOXA1 40 129 1.48E-08 TRANSFAC
FOXA1 43 89 2.57E-07 TRANSFAC
FOXA1 28 99 2.91E-07 TRANSFAC
FOXI1 232 347 4.49E-07 JASPAR
FOXA1 34 122 4.80E-07 TRANSFAC
FOXF2 128 214 3.00E-06 JASPAR
FOXD1 121 202 6.78E-06 JASPAR
NR4A2 226 326 1.07E-05 JASPAR
FOXA1 38 94 1.53E-04 TRANSFAC
MAF 220 324 2.61E-04 TRANSFAC
FOXQ1 150 221 2.86E-04 JASPAR
FOXO3 221 303 3.23E-04 JASPAR
MYB 110 139 5.55E-04 TRANSFAC
BACH2 11 36 1.08E-03 TRANSFAC
RORA 208 257 3.94E-03 JASPAR
NFATC2 250 320 4.21E-03 JASPAR
TFCP2 223 200 5.15E-03 TRANSFAC
ELK1 64 101 6.46E-03 JASPAR
SMAD3 106 83 6.92E-03 TRANSFAC
NFE2L2 277 344 9.47E-03 JASPAR
HLTF 81 120 9.77E-03 JASPAR
PPARA 69 84 1.18E-02 TRANSFAC
NFYA 110 152 1.57E-02 JASPAR
MYB 78 97 1.76E-02 TRANSFAC
GABPA 337 404 1.80E-02 JASPAR
RORA 176 237 1.80E-02 JASPAR
Table 1 Motif enrichment in cell type specific enhancers
(Continued)
MYB 73 107 1.83E-02 JASPAR
NF1 90 72 1.95E-02 TRANSFAC
EP300 170 153 2.05E-02 TRANSFAC
RORA 174 207 3.84E-02 JASPAR
ZEB1 25 15 4.47E-02 TRANSFAC
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in HMEC than MDAMB231, whereas 29 percent (n =
303) had higher expression levels in MDAMB231 than
HMEC (p < 0.05). Similarly, among the genes located near
MSEL only (n = 1,029), 55 percent (n = 567) had higher
expression levels in MDAMB231 than HMEC, whereas 33
percent (n = 335) had higher expression level in HMEC
than MDAMB231 (p < 0.05) (Additional file 2: Table S11).
Furthermore, active enhancers regulated gene expression
level more significantly than poised enhancers, and they
were engaged with promoters of target genes through DNA
looping [39]. Therefore, among cell-type specific enhancers,
only active enhancers as defined above were chosen, and
their putative specific target genes were matched by using
nearby cell type specific genes (within 100 kb). Finally,
we identified 316 genes, with higher expression levels in
HMEC than MDAMB231 near active HSEL (named as
HMEC selected genes). These genes were considered regu-
lated by 323 active HSEL (Additional file 2: Table S12).
Similarly, 342 genes were identified with higher expression
levels in MDAMB231 than HMEC near active MSEL
(named as MDAMB231 selected genes). Thus, 309 active
MSEL near these genes likely regulate their expression
(Additional file 2: Table S13). As an example, one of the ac-
tive HSEL, which was located 4.5 kb downstream of the
transcription start site of the gene, MARVELD1 seemed to
increase the expression level of MARVELD1, PI4K2A, and
AVPI1 genes in HMEC (Figure 5A). Another example was
the active MSEL, located in the intron of KANK2 genes,
and it may regulate the gene expression levels of SPC24,
LDLR, and KANK2 (Figure 5B). In order to verify the ex-
pression levels of these genes in both cell types, we per-
formed RT-qPCR by designing two primer sets for each
gene (Figure 5C). MARVELD1, PI4K2A, and AVPI1 genes,
near the HSEL in 10q24, were expressed higher in HMEC
than MDAMB231. Conversely, SPC24, LDLR, and KANK2
genes, near the MSEL in 19p13, were expressed at higher
levels in MDAMB231 than HMEC. According to our calcu-
lations of all enhancer specific gene, up to 8 nearby genes
are regulated by one active cell type specific enhancer, and
up to 8 different active cell type specific enhancers may
regulate one gene.
Lastly, the selected genes, which we identified as puta-
tively regulated by active cell type specific enhancers,
were further analyzed by performing gene ontology
(GO). When the difference between enrichment of genes
in both cell types for each GO biological process cat-
egory was measured, it was found that there were more
genes involved in proteolysis, epidermis development,
cell adhesion, chemotaxis, and wound healing in HMEC
selected genes than MDAMB231 selected genes (p <
0.02). On the other hand, of the genes that we proposed
to be under the control of MDAMB231 specific en-
hancers, a greater proportion were classified as being in-
volved in mitosis, cell cycle, DNA replication, chromatin
modification, and cell division, compared to HMEC se-
lective genes (p ≤ 0.03) (Figure 5D). In order to illustrate
relationships among differentially enriched GO process
categories of HMEC and MDAMB231 selected genes, a
comparison chart was generated using Quick GO [58]
(Additional file 1: Figure S20).
Genes, that are involved in differentially enriched GO
biological process categories are listed in a Table 2. For
example, LAMC2, which is involved in epidermis devel-
opment and cell adhesion, is overexpressed in HMEC
than MDAMB231. This gene is translated as a gamma 2
Laminin protein, which belong to a family of extracellu-
lar matrix glycoproteins that constitute basement mem-
branes. This gene is reported to be down-regulated in
various human cancers including breast cancers [59]. As
another example, SPC24, which is involved in mitosis,
cell cycle, and cell division process, is expressed at
higher levels in MDAMB231 than HMEC (Figure 5B).
SPC24 acts as a component of NDC80 kinetochore
complex, which is required for chromosome segregation
and spindle checkpoint activity. This gene is expressed
at higher level in grade 3 breast tumors, which are
poorly differentiated but highly proliferative [60]. SPC24
protein interacts with BUB1B protein according to the
previous study, which identified mitotic protein com-
plexes by using tandem-affinity purification of human
epithelial cells arrested in mitosis [61]. BUB1B is also
one of our MDAMB231 selected genes, regulated by the
MSEL in 15q15 (Table 2). BUB1B, which is also known
as Budding Uninhibited By Benzimidazules 1, encodes a
kinase involved in spindle checkpoint function. This pro-
tein inhibits the anaphase-promoting complex (APC) and
delays the onset of anaphase, which will ensure proper
chromosome segregation [62]. Previous studies reported
that BUB1B expression level is altered in breast tumors,
and the encoded protein is mutated in colorectal cancer
and breast cancer [63,64]. BUB1B protein is also known to
activate P53 via phosphorylation [65].
Next, we tested whether HMEC selected genes, which
may be regulated by HSEL, were involved in different bio-
logical processes from randomly chosen overexpressed
genes in HMEC (n = 316). Interestingly, the gene ontology
categories found above (i.e. proteolysis, epidermis develop-
ment, and cell adhesion) were not differentially enriched
between HMEC selected genes and random data set
(Additional file 2: Table S14). When we compared
MDAMB31 selected genes and randomly chosen over-
expressed genes in MDAMB231 (n = 342), the gene ontol-
ogy categories found above (i.e. mitosis, cell cycle, DNA
replication, chromatin modification, and cell division) were
not differentially enriched between MDAMB231 selected
genes and random data set (Additional file 2: Table S15).
As additional control datasets, we further tested whether
HMEC selected genes and randomly chosen overexpressed
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genes in MDAMB231 were involved in different biological
processes. Interestingly, GO process categories, differently
enriched between HMEC and MDAMB231 selected genes
(e.g. mitosis, cell cycle, cell division, cell adhesion, epidermis
development) were also differentially enriched in this com-
parison (Additional file 2: Table S16). Conversely, same
GO process categories were found to be differentially
enriched from comparison between MDAMB231 se-
lected genes and randomly chosen overexpressed genes
in HMEC (Additional file 2: Table S17). Therefore, we
propose that genes located proximal to HSEL or MSEL
seem to be involved in similar biological processes (e.g.
mitosis, cell cycle, cell division, cell adhesion, epider-
mis development) defined by differentially expression.
In summary, we did not find any distinct biological
process category that was enriched in genes located
proximal to HSEL or MSEL, compared to the differen-
tially expressed genes.
Conclusions
Recent ENCODE data reveal that the average number
of enhancers interacting with a TSS was 3.9, and the
average number of TSSs interacting with a distal elem-
ent was 2.5 in human cells [66]. Therefore, it is likely
that a large number of chromosomal contacts and
interactions are orchestrated by the three-dimensional
organization of the nucleus. In the spatial genome
organization, intra- and inter-chromosomal interac-
tions are mediated by nuclear components such as
transcription and replication machinery, polycomb
bodies, and contacts with the lamina [67-69]. In the
study from the Dekker lab, when the contact probabil-
ity was estimated across all chromosomes in human
cells, the contact probability decreased as the genomic
distance increased, showing a power-law behavior be-
tween genomic distance 500 kb and 7 Mb with an aver-
age exponent α ∼ 1.08. This observation led to the
suggestion that the organization of chromatin packing
was consistent with the behavior of a fractal globule, a
knot-free, polymer conformation [70].
Consequently, the proximity of genes to enhancers on
linear DNA, which controls their expression, has long
been thought to be the main factor of transcriptional
regulation via enhancers, called cis interactions. On the
other hand, trans interactions between enhancers and
genes on different chromosomes are possible to regulate
gene expression, but less frequent [70]. Methods that de-
fine interactions between DNA regions and gene expres-
sion include chromatin conformation capture (3C) and
its derivative methods (3C-seq, 4C-seq, 5C-seq, ChIA-
PET and HiC-seq) [71,72], expressed quantitative trait
loci (eQTLs) [45], the use of transcription activator-like
effector nucleases (TALEN or CRISPR) [73], and knock-
out mouse models [74,75]. However, methods employing
the capture of looping interactions by cross-linking
chromatin are technically demanding for cis interactions
since the background signals of random collisions (thus
false positives) are high. Therefore, it is almost impos-
sible to distinguish the interaction frequency of looping
between a gene and sites located within 50 kb away from
no looping [76]. Additionally, eQTL analyses, TALEN,
and transgenic mouse modeling cannot inform whether
the interactions are direct or indirect.
(See figure on previous page.)
Figure 5 Identification of target genes, which may be regulated by cell type specific enhancers. (A) UCSC genome browser screenshot
for an example of active HSEL (red bar) and their putative target genes (red arrows) (B) UCSC genome browser screenshot for an example of
active MSEL (red bar) and their putative target genes (red arrows) (C) Quantitative real-time RT-PCR analysis of putative target genes of active
HSEL (i.e. MARVELD1, PI4K2A, AVIPI1) and active MSEL (i.e. KANK2, SPC24, LDLR). Two primer sets located in the exons of each gene were used,
and the expression levels were presented relative to GAPDH expression. The error bars indicated the standard deviations from triplicate in HMEC
(black) and MDAMB231 (grey). (D) Gene ontology process categories, which were differentially enriched in the putative target genes of active
HSEL (black) and active MSEL (purple). x-axis indicated the -Log2 of p-value, calculated by performing chi-square between groups. The number
of genes belonged to each GO category was shown on the right side of the bar.
Table 2 A list of selected genes belong to differentially
enriched gene ontology (GO) biological process
GO process Genes
Proteolysis ADAMTS3, CPA4, CTSB, CTSC, HTRA1, KLK10, KLK5, KLK6,
KLK7, KLK8, MMP2, PREP, PRSS12, PRSS8, PYCARD, ST14,
ZFP90
Epidermis
development
ATP2A2, COL17A1, GJB5, KLK5, KLK7, KRT5, LAMC2,
PTHLH, S100A7, SPRR1A, SPRR1B
Cell adhesion ATP2A2, BOC, CDH3, CELSR2, CLDN1, CLSTN1, CTNND1,
DDR1, DSC2, DSC3, DST, F11R, FBLIM1, FLRT2, IGFBP7,
ITGB8, LAMC2, MTSS1, NID1, NRP2, NTM, PTK7, PTPRF,
SDK2, SIRPA, SPOCK1, SSPN, SSX2IP, TRIP6, ZYX
Chemotaxis CMTM6, CXCL14, IL8, PTAFR, S100A8, S100A9
Wound healing CDH3, IL1A, IL1B, SDC1, SERPINB2, TPM1
Mitosis ANAPC1, BIRC5, BUB1B, CCNF, CEP55, KIF2C, NCAPG2,
SPC24, TPX2, TUBB, TUBB2A, UBE2C
Cell cycle ANAPC1, BIRC5, BUB1B, CCNF, CDKN1B, CDKN3, CEP55,
DDX11, DUSP1, GSG2, ING1, ITGAE, KIF2C, LLGL2,
NCAPG2, PARD3B, PIN1, RPS6KB1, SPC24, STK11, TPX2,
UBE2C
DNA replication MCM10, POLD1, POLG2, RRM2, TK1
Chromatin
modification
ASF1B, ASXL1, EZH1, GSG2, H2AFY, MLL, NSD1, TAF5,
WHSC1
Cell division ANAPC1, BIRC5, BUB1B, CCNF, CEP55, KIF2C, LLGL2,
NCAPG2, PARD3B, SPC24, TPX2, UBE2C
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Here we evaluated cis interactions between enhancers
defined by histone modification and nearby genes in
normal breast epithelial cells (HMEC) and breast cancer
epithelial cells (MDAMB231). We showed that en-
hancers affected the expression levels of nearby genes
up to 750 kb away on average, but the effect diminished
as the distance increased. Enhancer status defined by
histone marks correlated with the expression levels of
nearby genes. Nucleosome-depletion, marked by FAIRE
signals was present in fifty percent of both poised and
active enhancers. By performing a motif search in en-
hancers and ChIP assays, we revealed transcription fac-
tors (e.g. TP63), which may be involved in regulating
breast epithelial enhancer-mediated gene expression.
We also identified putative target genes of the active cell
type specific enhancers by genomic distance (i.e. within
100 kb) with cell type specific gene expression. The pu-
tative target genes of cell type specific enhancers in nor-
mal breast epithelial cells (HSEL) were enriched in
proteolysis, epidermis development, and cell adhesion
biological process. On the other hand, more genes po-
tentially regulated by breast cancer cell type specific
enhancers (MSEL) were involved in mitosis, cell cycle,
DNA replication, chromatin modification, and cell div-
ision process. When we further compared expression
levels of these genes in normal breast and invasive
breast carcinoma tissues using the cancer genome atlas
(TCGA) breast cancer data [77,78], we found that 60
genes of MDAMB231 selected genes belonged to top 10
percent overexpressed genes in breast tumors than nor-
mal breast tissues, and 53 genes of HMEC selected
genes belonged to top 10 percent under-expressed genes
(Additional file 2: Table S18, Table S19). The list of these
genes includes not only a large number of known breast
cancer genes (e.g. CDH1, CDH3, BMP4, MTAP, CDKN2B),
revealed by previous studies using breast tumor tissues and
breast cancer cell lines [79,80] but also novel genes. The list
of more than 600 putative target genes of more than 600
selected cell type specific enhancers and identified tran-
scription factors will facilitate understanding of epigenetic
regulation in breast biology as well as cancer etiology.
Methods
Cell Culture
HMEC cells were obtained from Lonza (Lonza, Walkers-
ville, MD) and cultured under recommended conditions.
MDAMB231 cells were obtained from American Type
Culture Collection (ATCC, Manassas, VA). MDAMB231
cells were cultured in DMEM with 5% FBS.
FAIRE-seq library construction and sequencing
FAIRE assays were performed as described [42], with a
number of modifications. Briefly, the method was as fol-
lows: (1) intact cells were crosslinked (1% formaldehyde
in PBS); (2) nuclei were extracted from cells and re-
suspended in SDS lysis buffer; (3) chromatin DNA was
fragmented by sonication; (4) FAIRE DNA samples and
reverse-crosslinked input DNA were purified by phenol-
chloroform extraction. Two independent libraries were
constructed for each sample by using bar-coded adapters.
Each library was PCR amplified and confirmed by quantita-
tive real-time PCR (qPCR). Single-end DNA sequencing
(Illumina Hi-Seq 50 cycles) was performed at the USC Epi-
genome center. After passing through the pre-alignment
QC pipeline, which checked for things such as adapter and
poly-A contamination, reads were aligned with BWA 0.6.1
using the default parameters. The reference genome used
was GRCh37/HG19. Two independent assays per condi-
tion were analyzed separately, and then combined for fur-
ther analyses. HMEC FAIRE-seq data were deposited in
the NCBI GEO under accession number, GSE46074 [45].
MDAMB231 FAIRE-seq data were deposited in the NCBI
GEO number accession number, GSE49651.
Identification of FAIRE-seq peaks
After removing PCR artifacts and duplicates, each bam
file was filtered using a quality filter score of 30 by using
Samtools [81]. FindPeaks 4.0 software [82] was applied
in order to identify FAIRE-seq peaks. A triangle-based
distribution with a median length of 150 bp and 99.0%
confidence interval for peak pairs, which were unequal
between sample and input, were used. After peak identi-
fication, we calculated a p-value for each peak between
sample and input, and significant peaks were used for
further analysis.
Chromatin Immunoprecipitation library construction and
sequencing
HMEC Histone modification ChIP-seq data (H3K4me1,
me3, and H3K27Ac) were obtained from accession
number [GSE29611] through the NCBI Gene Expres-
sion Omnibus portal. ChIP assays were performed in
MDAMB231 as previously described [83]. Antibodies
used were anti-H3K4me1 (ab8895) (Abcam, Cambridge,
MA), anti-H3K27Ac (ab4729) (Abcam, Cambridge, MA),
anti-H3K4me3 (04-745) (Millipore Corp., Billerica, MA),
anti-P63 (39739) (Active Motif, Carlsbad, CA), and normal
rabbit IgG (sc-2027) (Santa Cruz Biotechnology, Santa
Cruz, CA). qPCR were performed on ChIP-isolated and
input DNA by using KAPA SYBR FAST qPCR Kits
(Kapa Biosystems, Woburn, MA) with primers, listed
in Additional file 2: Table S20.
ChIP-seq library construction and sequencing
Library was constructed and sequenced as previously
described above in the FAIRE-seq section. Two inde-
pendent assays per condition were analyzed separately
(Additional file 2: Table S2), and then the data were
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combined for further analyses. MDAMB231 ChIP-seq
data were deposited in the NCBI GEO number accession
number, GSE49651.
Identification of ChIP-seq peaks
Each bam file was filtered using quality filter score 30 after
removing PCR artifacts and duplicates by using Samtools
[81]. To identify enriched regions of histone modifications
(i.e. H3K4me1, H3K4me3, H3K27Ac) against input, MACS
software on histone ChIP-seq data was applied with default
settings [84]. For HMEC FAIRE-seq peaks overlapping
with ChIP-seq peaks analysis, ChIP-seq peaks identified
by Scripture [85] for histone marks, H3K27me3, H2A.Z,
H3K9me3, H3K79me2, H3K36me3, H3K20me1, H3K9Ac,
and H3K4me2, from ENCODE were used [66].
Cell type specific enhancer loci identification and states
Differently enriched H3K4me1 sites (i.e. HSEL and MSEL)
were identified from normalized HMEC and MDAMB231
H3K4me1 ChIP-seq tags by using findPeaks from HOMER
(http://homer.salk.edu/homer/) [20]: two ChIP samples
(HMEC H3K4me1 and MDAMB231 H3K4me1) were run
as ‘treatment’ and ‘control’ in order to identify significant
differences between the samples. To avoid from detecting
false positive peaks, 0.10% false discovery rate (FDR) was
used as a cut off. In order not to be biased by the different
yields of identified peaks in the two cell types, the top 2,000
H3K4me1 sites were selected for each of the HMEC
specific enhancer loci (HSEL) and MDAMB231 specific en-
hancer loci (MSEL). Identified enhancer loci were plotted
in the heatmaps and line graphs, which were generated by
using seqMINER software [40]. Poised and active enhancers
were categorized by using K-means linear clustering (n = 2)
with H3K27Ac ChIP-seq tags.
Shared enhancer loci identification
Shared enhancers were identified from normalized HMEC
and MDAMB231 H3K4me1 ChIP-seq tags and peaks by
using getDifferentialPeaks from HOMER (http://homer.
salk.edu/homer/) [20]. 2,000 shared enhancers, which have
similar ChIP-seq tag density in both cell types were selected
for further analysis as cell type specific enhancers were
studied.
Annotation and comparison between HMEC and
MDAMB231 cells
Identified peaks were analyzed by using mergePeaks and
annotatePeaks from HOMER (http://homer.salk.edu/
homer/) [20]. Annotated positions for promoters, exons,
introns, intergenic regions, and other features were based
on RefSeq transcripts and repeat annotations from Univer-
sity of California, Santa Cruz. Cell type specific enhancer
loci were visualized in genome using Circos software [86].
Motif discovery and enrichment measurements
In order to find regulatory motifs in enhancers, sets of pos-
ition weight matrices (PWMs) were used from FIMO and
TRANSFAC/Genome Trax [47,48,87]. FIMO analysis was
performed using the motif database, called JASPAR CORE
2009 vertebrates, downloaded from the MEME suite
(http://tools.genouest.org/tools/meme/meme-download.
html) [87]. P-value for output threshold utilized for
FIMO was 1e-4. Predicted ChIP-seq TFBS analysis, pre-
dicted TFBS in DNase hypersensitivity regions, and
TRANSFAC experimentally verified TFBS data from
Genome Trax were obtained. This database contains
motif matrices from best-scoring TF binding sites iden-
tified with a ChIP-chip or ChIP-seq fragment. The en-
richment of transcription motifs in enhancer regions
was calculated by performing chi-square test between
groups (P < 0.05).
Gene expression analysis between HMEC and MDAMB231
cells
Gene expression data for HMEC and MDAMB231
cells, which were detected in the affymetrix HG-U133
plus2 microarrays, were obtained from the accession
number [GSE33167] [33]. Gene expression levels for
both cells as well as p-values were processed by using
GEO2R [88]. Adjusted p-value cut off 0.05 was applied
to identify HMEC and MDAMB231 overexpressed
genes (3,174 genes for HMEC, 2,670 genes for
MDAMB231). Log fold change of gene expression level
between cell types was graphed using box plots in R
[89]. Log fold change value was used in order to iden-
tify top 300 overexpressed genes in each cell type,
which were about top 10 percent. The enrichment of
genes in each category was calculated by performing
chi-square test between groups. As control genes, 300
genes were randomly selected among 6,902 genes,
which contain 3,174 overexpressed genes in HMEC,
2,670 overexpressed genes in MDAMB231, and 1,058
genes significantly expressed in both cells.
Quantitative real time RT-PCR
Total RNA from HMEC and MDAMB231 cells were
isolated using Aurum Total RNA Mini Kit (Bio-Rad,
Hercules, CA). Isolated RNAs were reverse transcribed
to cDNA by using the qScript cDNA Synthesis Kit
(Quanta Biosciences, Gaithersburg, MD). Two primer
sets for each selected gene were designed (Additional
file 2: Table S20), and quantitative real-time PCR was
performed by using KAPA SYBR FAST qPCR Kits
(Kapa Biosystems, Woburn, MA). The raw expression
values were normalized to GAPDH mRNA expression
in each cell type.
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Western blot analysis
Whole cell extracts were prepared from HMEC and
MDAMB231 cells using SDS Lysis buffer supplemented
with protease inhibitor (Sigma-Aldrich, St. Louis, MO).
Equal amounts of protein from whole cell extracts were
separated by running on gradient polyacrylamide gels
(Bio-Rad, Hercules, CA), and transferred to Amersham
Hybond polyvinylidene difluoride (PVDF) membranes (GE
Healthcare, Buckinghamshire, UK). These blots were first
incubated with either a 1:2000 of anti-P63 (39739) (Active
Motif, Carlsbad, CA) or anti-beta-tubulin (MAB3408)
(Millipore Corp., Billerica, MA) for overnight, and followed
by incubation with their corresponding secondary anti-
bodies, anti rabbit-HRP-conjugated antibody (diluted
1:2500) (sc-2030) and anti mouse-HRP-conjugated
antibody (diluted 1:4000) (sc-2031) (Santa Cruz, Dallas,
Texas). Proteins were visualized using SuperSignal West
Pico Chemiluminescent Substrate (Pierce, Rockford, IL,
USA) and ChemiDoc XRS + Imaging System with Image
Lab (Bio-Rad, Hercules, CA).
Gene ontology
Gene ontology analysis was performed by using GEO2R
[88]. Same number of genes as samples was randomly
selected for controls, and the gene ontology of these
genes was also annotated. The enrichment of genes in
each gene ontology category was calculated by perform-
ing chi-square test between groups. In order to visualize
GO data, GO Slims and GO Term Comparison tool
from Quick GO [58] was used.
Comparison between the putative target genes of cell type
specific enhancers and differentially expressed genes in
breast tumor tissues
By using Oncomine database, released in March 2014,
the dataset from the cancer genome atlas (TCGA) breast
cancer studies was obtained [77,78]. The top 10 percent
over and under-expressed genes (n = 2,039 genes) detected
in the comparison between invasive breast carcinoma and
normal tissues were intersected with our putative target
genes.
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